home / stock / akba / akba news

AKBA News and Press, Akebia Therapeutics Inc.

Stock Information
Company Name: Akebia Therapeutics Inc.
Stock Symbol: AKBA
Market: NASDAQ
Website: akebia.com
Menu
AKBA AKBA Quote AKBA Short AKBA News AKBA Articles AKBA Message Board
Get AKBA Alerts

News, Short Squeeze, Breakout and More Instantly...
AKBA - Akebia (AKBA) Q4 2025 Earnings Call Transcript

2026-02-26 14:25:40 ET Image source: The Motley Fool. Thursday, February 26, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
AKBA - Akebia outlines 2026 pipeline expansion and expects Vafseo data catalysts in $1B dialysis market

2026-02-26 11:28:53 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript Akebia Post-Selloff: Revenue Dynamics And Upcom...

AKBA - Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript

2026-02-26 11:27:53 ET Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript

AKBA - Akebia GAAP EPS of -$0.05 misses by $0.01, revenue of $57.6M beats by $11.51M

2026-02-26 07:07:57 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts Akebia Q4 2025 Earnings Preview Quant snapsh...
AKBA - Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

Q4 2025 net product revenues of  $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo ® (vadadustat) revenue growth in 2026 through expanded access to therapy at ...

AKBA - Expected US Company Earnings on Thursday, February 26th, 2026

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

AKBA - Akebia Q4 2025 Earnings Preview

2026-02-25 10:07:43 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts Quant snapshot: Amerigo, Allianz lead strong buys as...
AKBA - Quant snapshot: Amerigo, Allianz lead strong buys as Ashford Hospitality, Hudson Pacific lag

2026-02-22 09:15:43 ET More on earnings Earnings week ahead: NVDA, CRM, HD, BIDU, LOW, DELL, SNOW, AMC, ZM, and more 33 of 52 S&P 500 companies post EPS growth in latest earnings week: Earnings scorecard Half of the S&P 500 utilities companies beat earnings t...

AKBA - Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akeb...

AKBA - Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

2026-02-13 16:57:51 ET Akebia Therapeutics, Inc. (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 9:30 AM EST... Read the full article on Seeking Alpha For further details see: Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securi...
Next 10